Cramer's 'Mad Money' Recap: Stocks With Great Earnings Visibility

Transocean

The third and last company that embodies great visibility is Transocean (RIG Quote), a contract driller, which Cramer owns for his charitable trust, Action Alerts PLUS, he said.

Cramer called Transocean "a principal beneficiary" of high oil rates and said it can get great prices for its deepwater rigs. The company, he said, has locked in high rates for years to come, with long-term contracts going out until 2010 and 2012.

Every time oil goes down, the stock gets hammered, but it shouldn't because its contracts are "ironclad," Cramer said.

Further, Transocean just completed its acquisition of its biggest competitor, GlobalSantaFe, he added. This "truly anticompetitive merger" should increase Transocean's bargaining power, enabling it to get better prices, he said.

Because of the limited supply of oil, there is an enormous backlog to building these rigs and it takes years to do so. Transocean, Cramer said, can get $600,000-a-day rental rates. He said its pricing power should stay strong over the next five years.

The worst thing to say about Transocean is that it has boring profits, he said.

All three companies -- First Solar, Medco Health and Transocean -- have five-year plans that ensure great earnings visibility. However, all three are all getting killed in the market, and investors should consider buying them now, Cramer advised.

BioMarin Pharmaceutical

BioMarin Pharmaceutical (BMRN Quote) recently received FDA approval for Kuvan, which is used for the treatment of phenylketonuria (PKU).

To explain to viewers the importance of this drug, Cramer called on BioMarin CEO Jean-Jacques Bienaime.

Kuvan, Bienaime said, is important for patients because it's the first and only FDA approved drug for PKU, which if untreated can cause neurological problems, including mental retardation.

Bienaime said he is confident Kuvan will be covered by most insurance companies. Some carriers might require a co-payment, but the maximum should be around $50 a month or $600 a year, he said.

Cramer called BioMarin a great speculative stock for those who are looking for a longer term horizon.